Total Payments
$147,648
2024 Payments
$43,570
Companies
22
Transactions
199
Payment Breakdown by Category
Consulting$91,988 (62.3%)
Other$38,942 (26.4%)
Travel$9,299 (6.3%)
Food & Beverage$5,691 (3.9%)
Research$1,728 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $91,988 | 35 | 62.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,800 | 23 | 17.5% |
| Honoraria | $13,142 | 16 | 8.9% |
| Travel and Lodging | $9,299 | 36 | 6.3% |
| Food and Beverage | $5,691 | 83 | 3.9% |
| Unspecified | $1,728 | 6 | 1.2% |
Payments by Type
General
$145,920
193 transactions
Research
$1,728
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Zogenix Inc. | $29,181 | 42 | $0 (2021) |
| UCB, Inc. | $26,371 | 44 | $0 (2024) |
| Neurelis, Inc. | $24,537 | 42 | $0 (2024) |
| UCB SA | $22,000 | 3 | $0 (2024) |
| Marinus Pharmaceuticals, Inc. | $20,597 | 16 | $0 (2024) |
| Azurity Pharmaceuticals, Inc. | $5,610 | 2 | $0 (2024) |
| EISAI INC. | $4,010 | 6 | $0 (2022) |
| JAZZ PHARMACEUTICALS INC. | $3,847 | 11 | $0 (2024) |
| Upsher-Smith Laboratories LLC | $3,400 | 1 | $0 (2018) |
| Greenwich Biosciences, Inc. | $2,131 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,570 | 38 | UCB SA ($22,000) |
| 2023 | $25,472 | 48 | Neurelis, Inc. ($11,956) |
| 2022 | $37,415 | 46 | UCB, Inc. ($24,201) |
| 2021 | $22,462 | 33 | Zogenix Inc. ($18,957) |
| 2020 | $14,294 | 21 | Zogenix Inc. ($10,224) |
| 2019 | $716.30 | 6 | NeuroPace, Inc. ($569.47) |
| 2018 | $3,400 | 1 | Upsher-Smith Laboratories LLC ($3,400) |
| 2017 | $319.28 | 6 | Lundbeck LLC ($156.79) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $144.54 | General |
| Category: NEUROLOGY | ||||||
| 12/18/2024 | Neurelis, Inc. | VALTOCO (Drug) | Consulting Fee | Cash or cash equivalent | $2,024.00 | General |
| Category: EPILEPSY | ||||||
| 12/06/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $103.25 | General |
| Category: EPILEPSY | ||||||
| 11/15/2024 | UCB SA | Fintepla (Drug) | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| Category: Neurology | ||||||
| 11/13/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $122.49 | General |
| Category: Neurology | ||||||
| 11/11/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Neurology | ||||||
| 11/10/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $109.01 | General |
| Category: EPILEPSY | ||||||
| 11/10/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $37.25 | General |
| 08/15/2024 | Marinus Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| 08/07/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $34.95 | General |
| Category: Neurology | ||||||
| 07/12/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $8,525.00 | General |
| 06/21/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: NEUROLOGY | ||||||
| 05/31/2024 | Azurity Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,805.00 | General |
| 05/16/2024 | Marinus Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| 05/01/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 04/22/2024 | Otter Pharmaceuticals, LLC | SYMPAZAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,338.00 | General |
| Category: Neurology | ||||||
| 03/27/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $32.61 | General |
| Category: NEUROLOGY | ||||||
| 03/18/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $87.50 | General |
| 03/13/2024 | Neurelis, Inc. | VALTOCO (Drug) | Consulting Fee | Cash or cash equivalent | $4,554.00 | General |
| Category: EPILEPSY | ||||||
| 03/13/2024 | Neurelis, Inc. | VALTOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: EPILEPSY | ||||||
| 03/13/2024 | Neurelis, Inc. | VALTOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $19.00 | General |
| Category: EPILEPSY | ||||||
| 03/13/2024 | Neurelis, Inc. | VALTOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $19.00 | General |
| Category: EPILEPSY | ||||||
| 02/21/2024 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 02/15/2024 | Azurity Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $2,805.00 | General |
| 02/09/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Food and Beverage | In-kind items and services | $77.63 | General |
| Category: Antiepileptic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SOTICLESTAT AS ADJUNCTIVE THERAPY IN PEDIATRIC AND YOUNG ADULT SUBJECTS WITH DRAVET SYNDROME (DS) | Takeda Pharmaceuticals U.S.A., Inc. | $1,728 | 6 |
About Dr. Michael Perry, MD
Dr. Michael Perry, MD is a Neurodevelopmental Disabilities healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1346364809.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Perry, MD has received a total of $147,648 in payments from pharmaceutical and medical device companies, with $43,570 received in 2024. These payments were reported across 199 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($91,988).
Ad
Practice Information
- Specialty Neurodevelopmental Disabilities
- Other Specialties Neurology with Special Qualifications in Child Neurology
- Location Fort Worth, TX
- Active Since 03/19/2007
- Last Updated 04/21/2021
- Taxonomy Code 2080P0008X
- Entity Type Individual
- NPI Number 1346364809
Products in Payments
- Fintepla (Drug) $55,973
- VALTOCO (Drug) $24,537
- ZTALMY (Drug) $19,317
- EPIDIOLEX (Drug) $3,777
- VIGADRONE (vigabatrin) for Oral Solution (Drug) $3,400
- Epidiolex (Drug) $2,131
- Brineura (Biological) $1,720
- SYMPAZAN (Drug) $1,338
- RNS System (Device) $581.39
- RNS Neurostimulator Kit (Device) $153.58
- SABRIL (Drug) $125.00
- DIACOMIT (Drug) $103.46
- APTIOM (Drug) $30.35
- VNS - Sentiva (Device) $19.04
- GENTLECATH GLIDE (Device) $13.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurodevelopmental Disabilities Doctors in Fort Worth
Dr. Alfred Balasa, M.d, M.D
Neurodevelopmental Disabilities — Payments: $367.78
Neurodevelopmental Disabilities $367.78
Nancy Hitzfelder, Md, MD
Neurodevelopmental Disabilities
Neurodevelopmental Disabilities
Joyce Mauk, Md, MD
Neurodevelopmental Disabilities
Neurodevelopmental Disabilities
Brooke Kimbrell, Md, MD
Neurodevelopmental Disabilities
Neurodevelopmental Disabilities